# A Study of QY201 Tablet in Subjects With Moderate to Severe Atopic Dermatitis

> **NCT05525715** · PHASE1,PHASE2 · UNKNOWN · sponsor: **E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.** · enrollment: 260 (estimated)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** 2mg QY201 tablets or 2mg QY201 placebo,BID
- **DRUG:** 5mg QY201 tablets or 5mg QY201 placebo,BID
- **DRUG:** 10mg QY201 tablets or 10mg QY201 placebo,QD
- **DRUG:** 10mg QY201 tablets or 10mg QY201 placebo,BID
- **DRUG:** 15mg QY201 tablets or 15mg QY201 placebo,BID
- **DRUG:** 20mg QY201 tablets or 20mg QY201 placebo,BID
- **DRUG:** 5mg QY201 tablets，BID
- **DRUG:** 10mg QY201 tablets，BID
- **DRUG:** 20mg QY201 tablets，BID
- **DRUG:** QY201 placebo，BID

## Key facts

- **NCT ID:** NCT05525715
- **Lead sponsor:** E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-10
- **Primary completion:** 2025-12
- **Final completion:** 2025-12
- **Target enrollment:** 260 (ESTIMATED)
- **Last updated:** 2022-09-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05525715

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05525715, "A Study of QY201 Tablet in Subjects With Moderate to Severe Atopic Dermatitis". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT05525715. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*